利福昔明联合门冬氨酸鸟氨酸治疗肝硬化肝性脑病患者的效果

Effect of Rifaximin Combined with Ornithine Aspartate in the Treatment of Hepatic Encephalopathy due to Cirrhosis

目的分析肝硬化肝性脑病患者采取利福昔明联合门冬氨酸鸟氨酸治疗效果。方法本次试验的120例患者均为本院2017年1月至2019年1月接收的肝硬化肝性脑病患者,根据入院单号、双号分为两组,每组60例,对照组实施单一的门冬氨酸鸟氨酸治疗,研究组接受利福昔明联合门冬氨酸鸟氨酸治疗,统计两组临床治疗效果,并评估治疗前后血氮水平、谷丙转氨酶(ALT)及血清总胆红素(TBIL)。结果在治疗总有效率方面,研究组为93.33%,对照组为80.00%,差异有统计学意义(P<0.05);治疗前,两组血氮、ALT及TBIL对比,差异无统计学意义(P>0.05);治疗后,研究组血氮、ALT及TBIL均低于对照组,差异有统计学意义(P<0.05)。结论在肝硬化肝性脑病患者的治疗过程中,利福昔明与门冬氨酸鸟氨酸联合应用不仅可以减轻患者的临床病症,而且有助于肝功能的改善。

Objective To analyze the therapeutic effect of rifaximin combined with ornithine aspartate in patients with hepatic encephalopathy due to cirrhosis.Methods A total of 120 patients with cirrhosis and hepatic encephalopathy received in our hospital from January 2017 to January 2019 were divided into two groups according to admission number,60 cases in each group.The control group was treated with single ornithine aspartate.The study group was treated with rifaximin combined with ornithine aspartate.The clinical efficacy of each group was counted,and the blood nitrogen levels,Alphaalanine aminotransferase(ALT)and serum total bilirubin(TBIL)before and after treatment were evaluated.Results The total effective rate of treatment in the study group was 93.33%and that in the control group was 80.00%.The study group was higher than that in the control group(P<0.05).There was no significant difference in blood nitrogen,ALT and TBIL between the two groups before treatment(P>0.05).After treatment,the study group was lower than that in the control group(P<0.05).Conclusion Rifamximine combined with ornithine aspartate can not only alleviate the clinical symptoms of patients with cirrhosis,but also improve the liver function,which is worthy of further clinical promotion and adoption.